Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter
Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta | Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta Therapeutics has found a permanent replacement.
TL;DRAI
Michael Severino (ex AbbVie VP) takes Sarepta CEO role as Elevidys revenue falls to $730.8M amid safety concerns. His background in R&D strategy, genetics, and precision medicine is crucial to restore confidence in the DMD pipeline.
741 words~3 min read
